Gurgaon Samachar

Basal Cell Carcinoma Pipeline Analysis Demonstrates Novel 25+ Therapies at the Horizon Expected to Transform the Treatment Paradigm

 Breaking News
  • No posts were found

Basal Cell Carcinoma Pipeline Analysis Demonstrates Novel 25+ Therapies at the Horizon Expected to Transform the Treatment Paradigm

March 15
11:15 2023
Basal Cell Carcinoma Pipeline Analysis Demonstrates Novel 25+ Therapies at the Horizon Expected to Transform the Treatment Paradigm

DelveInsight’s, “Basal Cell Carcinoma Pipeline Insight, 2023,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the Basal Cell Carcinoma pipeline landscape. It covers the Basal Cell Carcinoma pipeline drug profiles, including Basal Cell Carcinoma clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Basal Cell Carcinoma Emerging drugs, the Basal Cell Carcinoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Basal Cell Carcinoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Basal Cell Carcinoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Basal Cell Carcinoma clinical trials studies, Basal Cell Carcinoma NDA approvals (if any), and product development activities comprising the technology, Basal Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Basal Cell Carcinoma Pipeline Report

 

  • Over 25+ Basal Cell Carcinoma companies are evaluating 25+ Basal Cell Carcinoma pipeline therapies in various stages of development, and their anticipated acceptance in the Basal Cell Carcinoma market would significantly increase market revenue.

 

  • The leading Basal Cell Carcinoma Companies includes PellePharm, MedC Biopharma Corporation, AiViva BioPharma, MediWound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma, Epitome Pharmaceuticals, Transgene, Senhwa Biosciences, Palvella Therapeutics, Suzhou Kintor Pharmaceuticals, Leaf Vertical, and others.

 

  • Promising Basal Cell Carcinoma Pipeline Therapies includes BF-200 ALA, methyl-aminolevulinate, Patidegib, LDE225B, imiquimod, Vismodegib, Metvix® cream, and others.

 

  • The Basal Cell Carcinoma companies and academics are working to assess challenges and seek opportunities that could influence Basal Cell Carcinoma R&D. The Basal Cell Carcinoma pipeline therapies under development are focused on novel approaches to treat/improve Basal Cell Carcinoma.

 

Request a sample and discover the recent breakthroughs happening in the Basal Cell Carcinoma Pipeline landscape @ Basal Cell Carcinoma Pipeline Outlook Report

 

Basal Cell Carcinoma Overview

Basal Cell Carcinoma (BCC) is a common, locally invasive, keratinocyte cancer (also known as nonmelanoma cancer). It is the most common form of skin cancer. BCC is also known as rodent ulcer and basalioma. The main characteristics are: Slowly growing plaque or nodule, Skin colored, pink or pigmented, Varies in size from a few millimeters to several centimeters in diameter, Spontaneous bleeding or ulceration. Ultraviolet (UV) rays from the sun or from a tanning bed are the main cause of Basal Cell Carcinoma. The goal of treatment for Basal Cell Carcinoma is to remove the cancer completely.

 

Recent Developmental Activities in the Basal Cell Carcinoma Treatment Landscape

 

  • In December 2022, MediWound Ltd., a highly integrated biopharma firm that focuses on next-generation cell therapy treatments for tissue repair and regeneration, published a Phase I/II trial to assess the safety and efficacy of MW005 in the therapy of low-risk skin malignancies.

 

  • In December 2022: A major biopharmaceutical company in the investigation and development of RNAi therapeutics, Sirnaomics Ltd., published the interim data of part-one of an ongoing Phase IIb clinical study of STP705 for the treatment of Cutaneous Squamous Cell Carcinoma in Situ (isSCC). 

 

For further information, refer to the detailed Basal Cell Carcinoma Drugs Launch, Basal Cell Carcinoma Developmental Activities, and Basal Cell Carcinoma News, click here for Basal Cell Carcinoma Ongoing Clinical Trial Analysis

 

Basal Cell Carcinoma Emerging Drugs Profile

 

  • Patidegib: PellePharm

Patidegib is an investigational small molecule that inhibits hedgehog signaling. It is a topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. Topical patidegib is a first-in-class topical gel formulation of a proprietary hedgehog inhibitor exclusively licensed from Infinity Pharmaceuticals. Patidegib is currently evaluated in Phase III clinical trials for the treatment of BCCs.

 

  • AIV001: AiViva BioPharma

AIV001 is a novel formulation of a multi-kinase inhibitor combined with AiViva’s proprietary delivery technology, designed for prolonged drug release via intradermal treatment. AIV001 targets multiple pathways to reduce fibroplasia in overlapping phases of wound healing and scarring; targets VEGFR to limit the inflammation and fibrosis associated with rosacea; and inhibits or reduces neovascularization and cell proliferation associated with certain cancers. AIV001 is in Phase I/II clinical studies for the treatment of patients with Basal Cell Carcinoma.

 

Basal Cell Carcinoma Pipeline Therapeutics Assessment

There are approx. 25+ key companies which are developing the therapies for Basal Cell Carcinoma. The companies which have their Basal Cell Carcinoma drug candidates in the most advanced stage, i.e. Phase III include, PellePharm.

 

Find out more about the Basal Cell Carcinoma Pipeline Segmentation, Therapeutics Assessment, and Basal Cell Carcinoma Emerging Drugs @ Basal Cell Carcinoma Treatment Landscape

 

Scope of the Basal Cell Carcinoma Pipeline Report

 

  • Coverage- Global

 

  • Basal Cell Carcinoma Companies- PellePharm, MedC Biopharma Corporation, AiViva BioPharma, MediWound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma, Epitome Pharmaceuticals, Transgene, Senhwa Biosciences, Palvella Therapeutics, Suzhou Kintor Pharmaceuticals, Leaf Vertical, and others.

 

  • Basal Cell Carcinoma Pipeline Therapies- BF-200 ALA, methyl-aminolevulinate, Patidegib, LDE225B, imiquimod, Vismodegib, Metvix® cream, and others

 

  • Basal Cell Carcinoma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration 

 

Dive deep into rich insights for drugs for Basal Cell Carcinoma Pipeline Companies and Therapies, click here @ Basal Cell Carcinoma Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Basal Cell Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Basal Cell Carcinoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Patidegib: PellePharm
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. IO103: IO Biotech
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. AIV001: AiViva BioPharma
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Cannabidiol: Leaf Vertical
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Basal Cell Carcinoma Key Companies
  21. Basal Cell Carcinoma Key Products
  22. Basal Cell Carcinoma- Unmet Needs
  23. Basal Cell Carcinoma- Market Drivers and Barriers
  24. Basal Cell Carcinoma- Future Perspectives and Conclusion
  25. Basal Cell Carcinoma Analyst Views
  26. Appendix

 

Got Queries? Find out the related information on Basal Cell Carcinoma Mergers and acquisitions, Basal Cell Carcinoma Licensing Activities @ Basal Cell Carcinoma Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Categories